MENU
+Compare
NRXP
Stock ticker: NASDAQ
AS OF
Jun 27 closing price
Price
$3.42
Change
-$0.08 (-2.29%)
Capitalization
66.7M

NRXP NRX Pharmaceuticals Forecast, Technical & Fundamental Analysis

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases... Show more

NRXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for NRXP with price predictions
Jun 27, 2025

Aroon Indicator for NRXP shows an upward move is likely

NRXP's Aroon Indicator triggered a bullish signal on June 20, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 106 similar instances where the Aroon Indicator showed a similar pattern. In of the 106 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NRXP advanced for three days, in of 211 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for NRXP moved out of overbought territory on June 17, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 40 cases where NRXP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on June 27, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NRXP as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NRXP turned negative on June 18, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NRXP broke above its upper Bollinger Band on June 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NRXP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (16.366). P/E Ratio (0.358) is within average values for comparable stocks, (58.189). NRXP's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.247).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
NRXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

NRXP is expected to report earnings to fall 85.29% to -5 cents per share on May 14

NRX Pharmaceuticals NRXP Stock Earnings Reports
Q1'24
Est.
$-0.05
Q1'25
Beat
by $0.19
Q4'24
Missed
by $0.66
Q4'23
Missed
by $0.43
Q3'23
Beat
by $0.04
The last earnings report on May 15 showed earnings per share of -34 cents, beating the estimate of -52 cents. With 259.89K shares outstanding, the current market capitalization sits at 66.70M.
A.I. Advisor
published General Information

General Information

is a blank check company, which engages in a stock exchange, asset acquisition, stock purchase, and reorganization

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1201 Orange Street
Phone
+1 484 254-6134
Employees
N/A
Web
https://nrxpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CBTTF0.04N/A
+0.42%
Cathedra Bitcoin Inc
SCGPY2.78N/A
N/A
Serco Group Plc.
WFCNP1.50N/A
N/A
Wells Fargo & Co.
DRETF10.97N/A
N/A
Dream Office Real Estate Investment Trust
CMSQY25.88-0.06
-0.23%
Computershare Ltd.

NRXP and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NRXP has been closely correlated with CDTX. These tickers have moved in lockstep 85% of the time. This A.I.-generated data suggests there is a high statistical probability that if NRXP jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NRXP
1D Price
Change %
NRXP100%
-2.29%
CDTX - NRXP
85%
Closely correlated
+0.24%
NBY - NRXP
84%
Closely correlated
+0.97%
NCNA - NRXP
84%
Closely correlated
N/A
RNAC - NRXP
83%
Closely correlated
-6.81%
ALLR - NRXP
83%
Closely correlated
+2.12%
More

Groups containing NRXP

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NRXP
1D Price
Change %
NRXP100%
-2.29%
NRXP
(20 stocks)
5%
Poorly correlated
-0.67%